The development of novel HER2-directed ADCs [12] in the treatment of breast cancer with low expression of HER2 has dramatically changed the biologic and clinical treatment landscapes of HER2-negative BCs, and has been the driving force of the introduction of “HER2-low” subtype in BC. Here, ERBB2 is linked to breast carcinoma.